Studying CT3001 for advanced solid tumors
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests an experimental drug called CT3001 for people with advanced solid tumors that haven't responded to other treatments. The goal is to see if it's safe and effective, and for some patients with colorectal cancer, it may be combined with standard chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a type of advanced solid tumor (like colon, lung, or breast cancer) that has spread or cannot be removed with surgery, and standard treatments either didn't work or aren't available.
- You should be well enough to perform your daily activities (ECOG 0 or 1) and have a life expectancy of at least 3 months.
- Your blood counts (hemoglobin, neutrophils, platelets) and liver/kidney function must be within certain limits.
- You must not be pregnant or nursing, and if of childbearing potential, must use reliable contraception during the study and for 3 months after.
- You cannot have had major surgery, certain heart conditions, severe infections, or used other investigational drugs recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests a new drug called IBI3028 in people with advanced cancers that cannot be removed by surgery or have spread. The study aims to find the right dose and understand how the drug works in your body.
This trial tests a new drug (TQB2930) combined with chemotherapy, with or without another drug called bevacizumab, for people whose colorectal cancer has spread or cannot be removed by surgery and has a specific protein called HER2. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This Phase 1 trial studies a new cancer medicine (IBI343) that targets certain tumor cells to see how safe it is and how well it may work. You may be eligible if you have advanced, hard-to-remove cancers and your tumor has a specific marker called CLDN18.2.
This trial is testing whether a new drug called CT7439 can help people with advanced solid tumors that have not responded to other treatments. It is a phase 1/2 study that also checks the drug's safety and how well it works.
This Phase 1 trial tests DFP-14927, a new study drug, in adults with advanced solid tumors that have not responded to standard treatments. It’s designed to see if the drug is safe and to learn how it works in people with limited treatment options.
This trial tests a new drug called IBI3001 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and effective against different types of cancer.
Hear when a new Solid Tumor, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.